Production (Stage)
BioVaxys Technology Corp.
BVAXF
$0.0229
$0.00031.33%
OTC PK
| 04/30/2025 | 01/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 10.64% | -28.72% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.43% | -26.67% | |||
| Operating Income | -7.43% | 26.67% | |||
| Income Before Tax | -23.01% | 62.53% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -23.01% | 62.53% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -23.01% | 62.53% | |||
| EBIT | -7.43% | 26.67% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -10.34% | 65.06% | |||
| Normalized Basic EPS | 4.76% | 25.00% | |||
| EPS Diluted | -10.34% | 65.06% | |||
| Normalized Diluted EPS | 4.76% | 25.00% | |||
| Average Basic Shares Outstanding | 9.92% | 8.11% | |||
| Average Diluted Shares Outstanding | 9.92% | 8.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||